Journal CME - 2015 April
Back to Journal CME - 2015 April

Journal CME - 2015 April

Summary:

Prothrombin complex concentrates (PCCs) are recommended in preference to other treatments such as therapeutic plasma for urgent reversal of vitamin K antagonists. PCCs contain either three or four coagulation factors (factors II, IX, and X, with or without factor VII) and, depending on formulation, low doses of coagulation inhibitors such as protein C, protein S, and heparin (table 1). There are considerable variations among countries in the availability and licensing status of PCCs. For example, four-factor PCCs have been used for many years in Europe, where their license is not restricted to vitamin K antagonist reversal—they have broad approval for “treatment and prophylaxis of bleeding in acquired deficiency of the prothrombin complex coagulation factors.” In the United States, however, the first four-factor PCC was only recently approved, specifically for urgent reversal of vitamin K antagonist therapy.

CME Credit: 1.00 AMA PRA Category 1 Credit™

 


Required Hardware / Software:
Adobe Acrobat Reader, Internet connection. Web browser version must have been released within the last three years.

Activity Release Date:
03/17/2015

Activity Expiration Date:
03/16/2018

  • List Price: $20.00 USD
  • Member Price: $0.00 USD

 
Want to save more?
to see if you qualify for a lower rate.
Members save $20.00 USD or more
Item Details:

Learning Objectives:
After successfully completing this activity, the learner will be able to do the following:

  • Administer prothrombin complex concentrate (PCC) in compliance with the approved and unapproved indications in the United States 
  • Define the components that make up the PCC...
Back to Journal CME - 2015 April
View More
Back to Product Detail

Thank You Industry Supporters

Whose contributions allow the American Society of Anesthesiologists® to create world-class education and resources to improve patient care and outcomes.

Learn More